Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1

Reuters

06/25

Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1

Mira Pharmaceuticals Inc. $(MIRA)$ has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2546217559"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546217559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546217559?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546217559","market":"fut","top_or_hot":-1,"title":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mira Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-25 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mira Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRA","symbol_name":"Mira Pharma","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL99FqMP:1","article_id":"2546217559","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546217559","pubTimestamp":1750852827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1. Mira Pharmaceuticals Inc.  has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRA":"Mira Pharma","BK4007":"制药"},"translate_title":"Mira Pharmaceuticals Inc.正在等待监管部门批准收购SKNY Pharmaceuticals，旨在通过SKNY-1彻底改变减肥和戒烟市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":0.9},"content_text":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1\n    \n\n        Mira Pharmaceuticals Inc. $(MIRA)$ has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042290) on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}